Analysts Set Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Price Target at $52.80

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) have been given an average rating of “Moderate Buy” by the seven brokerages that are covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $52.80.

A number of brokerages have recently weighed in on COLL. HC Wainwright reiterated a “buy” rating and issued a $60.00 price target (up from $46.00) on shares of Collegium Pharmaceutical in a report on Friday, January 9th. Wall Street Zen upgraded shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Barclays dropped their target price on shares of Collegium Pharmaceutical from $58.00 to $56.00 and set an “overweight” rating on the stock in a report on Friday, January 9th. Zacks Research lowered shares of Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 6th. Finally, Weiss Ratings reiterated a “buy (b-)” rating on shares of Collegium Pharmaceutical in a research note on Monday, December 29th.

Collegium Pharmaceutical Price Performance

COLL opened at $46.28 on Thursday. The company has a market capitalization of $1.46 billion, a P/E ratio of 28.75 and a beta of 0.64. The company has a 50-day moving average of $47.39 and a 200-day moving average of $40.86. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.27 and a current ratio of 1.36. Collegium Pharmaceutical has a 1-year low of $23.23 and a 1-year high of $50.79.

Insider Activity at Collegium Pharmaceutical

In related news, Director Rita J. Balice-Gordon sold 3,650 shares of Collegium Pharmaceutical stock in a transaction dated Friday, December 5th. The shares were sold at an average price of $47.03, for a total value of $171,659.50. Following the sale, the director directly owned 52,629 shares in the company, valued at $2,475,141.87. This trade represents a 6.49% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Scott Dreyer sold 17,600 shares of the business’s stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $48.17, for a total transaction of $847,792.00. Following the transaction, the executive vice president directly owned 103,613 shares of the company’s stock, valued at $4,991,038.21. The trade was a 14.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 2.51% of the company’s stock.

Hedge Funds Weigh In On Collegium Pharmaceutical

Several hedge funds and other institutional investors have recently made changes to their positions in COLL. Rubric Capital Management LP increased its position in Collegium Pharmaceutical by 5.3% in the 2nd quarter. Rubric Capital Management LP now owns 3,157,743 shares of the specialty pharmaceutical company’s stock valued at $93,374,000 after acquiring an additional 157,743 shares during the period. Vanguard Group Inc. grew its stake in shares of Collegium Pharmaceutical by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 2,256,254 shares of the specialty pharmaceutical company’s stock worth $104,465,000 after purchasing an additional 29,876 shares in the last quarter. Principal Financial Group Inc. increased its holdings in shares of Collegium Pharmaceutical by 0.3% during the fourth quarter. Principal Financial Group Inc. now owns 1,313,662 shares of the specialty pharmaceutical company’s stock valued at $60,823,000 after purchasing an additional 3,891 shares during the period. Massachusetts Financial Services Co. MA increased its holdings in shares of Collegium Pharmaceutical by 65.3% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 1,312,655 shares of the specialty pharmaceutical company’s stock valued at $60,776,000 after purchasing an additional 518,721 shares during the period. Finally, Emerald Advisers LLC raised its stake in shares of Collegium Pharmaceutical by 1.3% during the second quarter. Emerald Advisers LLC now owns 837,549 shares of the specialty pharmaceutical company’s stock valued at $24,766,000 after purchasing an additional 11,074 shares in the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.